US FDA approves AbbVie’s interleukin-23 inhibitor, Skyrizi to treat moderately to severely active Crohn's disease

Press/Media

Period	21 Jun 2022

Media coverage

Title	US FDA approves AbbVie’s interleukin-23 inhibitor, Skyrizi to treat moderately to severely active Crohn's disease
Media name/outlet	PharmaBiz
Country/Territory	India
Date	21/06/22
URL	www.pharmabiz.com/NewsDetails.aspx?aid=151532&sid=2
Persons	Marla Dubinsky